Article Sidebar
Views pdf: 91
TREATMENT OUTCOMES OF UPPER GASTROINTESTINAL BLEEDING ASSOCIATED FACTORS IN PATIENTS RECEIVING ANTIPLATELET THERAPY
Main Article Content
Abstract
Objectives: To evaluate the treatment outcomes, and to analyze some associated factors related to the treatment outcomes of upper gastrointestinal bleeding in patients receiving antiplatelet therapy. Methods: A cross – sectional descriptive study on 41 patients with peptic ulcer bleeding who were using antiplatelet therapy from August 2024 to July 2025 at Thai Nguyen Central Hospital. Results: The mean age was 71,2 ± 10,6 years, with 80,5% male. Most patients received single antiplatalet therapy (82,9%). Endoscopic hemostasis was performed in 29,3% of patients (17/41) and rebleeding during hospitalization occurred in 12,2% of cases. The proportions of patients requiring surgery and transarterial embolization were 2.4% and 4.9%, respectively. Blood transfusion was required in 73.2% of patients, and the median length of hospital stay was 6 (5–7) days. Analysis showed that rebleeding was associated with history of upper gastrointestinal bleeding (p = 0,04) and ulcer size ≥ 2cm (p = 0,04). Longer hospital stays were observed in patients aged > 70 years (p = 0,003), those with rebleeding (p = 0,03), and those with heart failure (p = 0,01). Conclusion: The overall treatment success rate was high, and endoscopic hemostasis was achieved in most patients, although recurrent bleeding remained a significant challenge. History of upper gastrointestinal bleeding and ulcer size ≥ 2 cm were associated with an increased risk of rebleeding and should be carefully considered during follow-up and management.
Article Details
Keywords
upper gastrointestinal bleeding, antiplatelet, rebleeding
References
2. Venerito M, Schneider C, Costanzo R, Breja R, Rohl FW, Malfertheiner P. Contribution of Helicobacter pylori infection to the risk of peptic ulcer bleeding in patients on nonsteroidal anti-inflammatory drugs, antiplatelet agents, anticoagulants, corticosteroids and selective serotonin reuptake inhibitors. Aliment Pharmacol Ther. 2018;47(11):1464-71.
3. Sarajlic P, Simonsson M, Jernberg T, Back M, Hofmann R. Incidence, associated outcomes, and predictors of upper gastrointestinal bleeding following acute myocardial infarction: a SWEDEHEART-based nationwide cohort study. Eur Heart J Cardiovasc Pharmacother. 2022; 8(5):483-91.
4. Laursen SB, Stanley AJ, Laine L, Schaffalitzky de Muckadell OB. Rebleeding in peptic ulcer bleeding - a nationwide cohort study of 19,537 patients. Scand J Gastroenterol. 2022;57(12):1423-9.
5. Sung JJ, Lau JY, Ching JY, Wu JC, Lee YT, Chiu PW, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med. 2010;152(1):1-9.
6. Camus M, Jensen DM, Kovacs TO, Jensen ME, Markovic D, Gornbein J. Independent risk factors of 30-day outcomes in 1264 patients with peptic ulcer bleeding in the USA: large ulcers do worse. Aliment Pharmacol Ther. 2016;43(10): 1080-9.
7. Wong SK, Yu LM, Lau JY, Lam YH, Chan AC, Ng EK, et al. Prediction of therapeutic failure after adrenaline injection plus heater probe treatment in patients with bleeding peptic ulcer. Gut. 2002;50(3):322-5.
8. Antunes C, Braitman L, Katz P. Accurate Identification of Prolonged Length of Stay on Admission in Patients with Upper Gastrointestinal Bleeding: 1133. Official journal of the American College of Gastroenterology | ACG. 2016;111: S495.